Augmented CD4+ T-cell and humoral responses after repeated annual influenza vaccination with the same vaccine component A/H1N1pdm09 over 5 years by Trieu, Mai Chi et al.
ARTICLE OPEN
Augmented CD4+ T-cell and humoral responses after repeated
annual influenza vaccination with the same vaccine component
A/H1N1pdm09 over 5 years
Mai-Chi Trieu1,2, Fan Zhou1,2, Sarah Larteley Lartey1,2, Saranya Sridhar3,6, Siri Mjaaland2,4 and Rebecca Jane Cox1,2,5
Annual seasonal influenza vaccination is recommended for high-risk populations and often occupational groups such as healthcare
workers (HCWs). Repeated annual vaccination has been reported to either have no impact or reduce antibody responses or
protection. However, whether repeated vaccination influences T-cell responses has not been sufficiently studied, despite the
increasing evidence of the protective roles of T-cell immunity. Here, we explored the impact of repeated annual vaccination with
the same vaccine strain (H1N1pdm09) over multiple seasons in the post-2009 pandemic era and showed that repeated vaccination
increased both T-cell and humoral responses. Using the T-cell FluroSpot and intracellular cytokine-staining, the hemagglutination
inhibition (HI), and the memory B-cell (MBC) ELISpot assays, we investigated pre- and postvaccination T cells, antibodies, and MBCs
in a cohort of HCWs repeatedly vaccinated with H1N1pdm09 for 5 years (pandemic vaccination in 2009 and subsequently annual
seasonal vaccination containing H1N1pdm09 during 2010–2013). We found that the prevaccination H1N1pdm09-specific T cells,
antibodies, and MBCs were significantly increased after 3–4 repeated vaccinations and maintained at high levels throughout
seasons 2012 and 2013. The cross-reactive IFN-γ-secreting CD4+ cells recognizing conserved viral external or internal epitopes were
also maintained throughout 2012 and 2013. Repeated vaccination improved the multifunctional memory CD4+ responses.
Particularly, the IFN-γ+TNF-α+CD4+ T cells were boosted following each vaccination. HI antibodies were significantly induced after
each vaccination over 5 years. Our findings indicate a broad impact of repeated annual vaccination, even with the same vaccine
component, on the influenza-specific T-cell and humoral immunity and support the continuing recommendation of annual
influenza vaccination.
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INTRODUCTION
Influenza virus remains a major health challenge due to its
continuous ability to evade the hosts’ immunity. Annual seasonal
influenza vaccination is the main method of prophylaxis for high-
risk populations and healthcare workers (HCWs) providing
protection against influenza A/H1N1, A/H3N2, and B viruses.1 In
2009, a novel H1N1 virus (H1N1pdm09) emerged and caused the
first pandemic of the twenty-first century. HCWs were prioritized
for pandemic vaccination to protect their patients and themselves,
and maintain the integrity of the healthcare system.2 The AS03-
adjuvanted monovalent H1N1pdm09 vaccine was used during the
pandemic in Norway and provided protection against laboratory-
confirmed influenza infection and hospitalization.3 The
H1N1pdm09 virus continued to circulate after 2009 replacing
earlier H1N1 strains and was therefore included in the seasonal
vaccines as the A/H1N1 component during seasons 2010−2016.
Antibodies directed against the main viral surface glycoprotein,
hemagglutinin (HA), can neutralize the influenza virus. The
hemagglutination inhibition (HI) assay has been widely used to
evaluate the HA-specific antibody responses. An HI titer of 40 is
established as a surrogate correlate of protection against influenza
at a 50% protective threshold.4 Inactivated influenza vaccines are
standardized by the quantity of HA of each strain and induce HI
antibodies after vaccination. Moreover, T cells have recently
gained more recognition for their protective roles. Preexisting
influenza-specific interferon (IFN)-γ-secreting CD4+ or CD8+ T cells
can recognize conserved viral epitopes and provide cross-
protection from heterosubtypic influenza A viruses, even in the
absence of protective antibodies.5–8
Importantly, influenza vaccines have been used for decades;
however, the long-term impact of repeated annual vaccination on
antibody responses is not fully understood9–11 and there are
limitations of our knowledge of its impact on T-cell responses. The
emergence of the H1N1pdm09 virus and its inclusion as the A/
H1N1 component in the seasonal vaccines for multiple years
provided a unique opportunity to investigate the impact of
repeated vaccination. Previously, we investigated the impact of
repeated annual vaccination upon preexisting influenza-specific
CD8+ and CD4+ T cells prior to two consecutive influenza seasons
in HCWs who were either repeatedly vaccinated or only received a
pandemic vaccination.12 In the current study, we further explored
the impact of annual vaccination on T cells, particularly
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CD4+ T cells, and humoral immunity by assessing paired pre- and
postvaccination T cell, antibody, and memory B-cell (MBC)
responses in repeatedly vaccinated HCWs over 5 years. We have
extended our previous findings to show that repeated annual
vaccination with the same strain augmented both humoral and
CD4 T-cell responses, maintained the cross-reactive IFN-γ-secret-
ing CD4+ T cells recognizing viral external and internal epitopes,
while increasing multifunctional memory CD4+ responses. Our
findings have implications for the seasonal influenza vaccination
strategy and vaccine development.
RESULTS
Study population
Fourteen HCWs (mean age 41.2 years old, range 30–63 years), who
received the AS03-adjuvanted pandemic vaccine in 2009 and
subsequently annual seasonal vaccination during seasons
2010–2013, were included in this study (Fig. 1). Most HCWs (12/
14) were female, worked on a clinical ward, and had history of
previous seasonal vaccination before 2009 (Supplementary-Table 1).
Maintenance of H1N1pdm09-specific IFN-γ-secreting T cells
The magnitude of preexisting and vaccine-induced H1N1pdm09-
specific T cells was assessed before and after seasonal vaccination
in 2012 and 2013 by measuring the IFN-γ-, interleukin(IL)-2-, or
double-cytokine IFN-γIL-2 secretion against the split H1N1pdm09
virus and the H1N1-specific internal protein peptide pools: matrix
1 (M1), nucleoprotein (NP), and polymerase-basic 1 (PB1).
All cytokine-secreting T cells against the split virus were
maintained at high levels throughout the two seasons, although
no significant boost of these responses was observed after
vaccination (Fig. 2a). The IFN-γ-secreting T cells recognizing the
three internal proteins were maintained throughout 2012 and
2013 (Fig. 2c, e, g). However, we observed a decline in IL-2-
secreting T cells recognizing M1 and NP after 1 year and a low but
stable level of double-cytokine-secreting cells, leading to an
increased IFN-γ/IL-2 ratio over time (Fig. 2d, f). Whereas IFN-γ
dominated the responses against PB1, as there was almost no IL-2
or double-cytokine secretion (Fig. 2g, h). The dominant IFN-γ trend
was not observed in the H1N1pdm09-specific T cells against the
split virus (containing mainly surface glycoproteins), which had a
balanced IFN-γ/IL-2 response (Fig. 2b).
Maintenance of cross-reactive IFN-γ-secreting CD4+ T cells
The influenza-specific cross-reactive CD4+ T-cell responses were
investigated using separate CD4 external or internal peptide
pools. We found that the cross-reactive IFN-γ- or IL-2-secreting
CD4+ T cells against external epitopes were maintained, while
there was a trend of increased double-cytokine responses after
vaccination (p= 0.094) (Fig. 3a). The cross-reactive IFN-γ- or
double-cytokine-secreting CD4+ T cells against internal epitopes
were maintained throughout the two seasons, whereas the IL-2-
secreting cells declined after vaccination in 2012 (p= 0.088) and
further in 2013 (p= 0.003) (Fig. 3e), resulting in the shift toward
IFN-γ dominance over time (Fig. 3f). However, the trend of
predominant IFN-γ was not observed in the cross-reactive
responses to external epitopes (Fig. 3b).
To further examine this trend, T-cell responses were assessed in
a control group of HCWs who were only vaccinated with the AS03-
adjuvanted H1N1pdm09 vaccine in 2009 and received no further
seasonal vaccinations. We have previously reported a decline in all
cytokine-secreting cross-reactive CD4+ T cells against internal
epitopes and H1N1pdm09-specific T cells after a year in these
HCWs (Fig. 3g and Supplementary-Fig. 1a).12 We assessed the
CD4+ T cells against external epitopes and observed a decline in
Fig. 1 The study flow chart. Healthcare workers (HCWs) were vaccinated with a single dose of the AS03-adjuvanted monovalent pandemic
H1N1pdm09 vaccine (European Clinical Trials Database, EudraCT 2009-016456-43; www.clinicaltrials.gov, NCT01003288). During
2010–2013 seasons, HCWs were vaccinated every year with the trivalent seasonal inactivated vaccines, containing the H1N1pdm09 virus
as the A/H1N1 component during the whole study period. The A/H3N2 and B strains included in the seasonal vaccines changed between
seasons during 2010–2013. The figure shows the inclusion criteria for this study, which were repeated annual vaccination between 2010 and
2013, and provision of peripheral blood monocular cells (PBMC) prevaccination (D0) and 21 days postvaccination (D21) in 2012 and
2013 seasons
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double-cytokine secretion after a year, although not significant
(Fig. 3c). A balanced IFN-γ/IL-2 response against the CD4 external
epitopes and split H1N1pdm09 virus was found in this control
group (Fig. 3d and Supplementary-Fig. 1b). However, no trend of
increasing IFN-γ/IL-2 ratio in the CD4+ T cells specific for viral
internal epitopes was observed, supporting the impact of
repeated vaccination in favoring IFN-γ responses (Fig. 3h).
Vaccine-induced boost of multifunctional IFN-γ+ and memory
CD4+ T cells
Next, we explored the quality of H1N1pdm09-specific CD4+ T cells
before and after vaccination in 2012 and 2013 by assessing the
cytokine profile and memory subsets against the split H1Npdm09
antigen in the intracellular cytokine-staining assay (n= 5). The
cytokine profile included seven cytokine-secreting subsets: triple
Fig. 2 The magnitude of H1N1pdm09-specific T-cell responses during seasons 2012 and 2013. The single IFN-γ- or IL-2-, or double-cytokine
IFN-γIL-2-secreting T cells against a the split H1N1pdm09 virus, the H1N1-specific viral internal proteins: c M1, e NP, or g PB1 prevaccination
(D0) (light) and at 21 days postvaccination (D21) (dark) were measured in the T-cell FluoroSpot assay. Each symbol represents one individual’s
response with the horizontal lines representing the mean magnitudes of cytokine-secreting cells per 106 PBMC with standard error of the
mean (s.e.m.). The IFN-γ to IL-2 ratio was calculated for each participant at each time point and the mean ratios with s.e.m. are shown against b
the split H1N1pdm09 virus, the viral internal proteins: d M1, f NP, or h PB1. The dotted line indicates the IFN-γ/IL-2 ratio of 1 showing a
balanced IFN-γ and IL-2 response. An IFN-γ/IL-2 ratio above or below 1 shows a predominant IFN-γ or IL-2 response, respectively. nsp > 0.05, *p
< 0.05, **p < 0.01
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producer (IFN-γ+IL-2+ tumor-necrosis-factor (TNF)-α+), double
producers (IFN-γ+IL-2+, IFN-γ+TNF-α+, IL-2+TNF-α+), and single
producers (IFN-γ+, IL-2+, TNF-α+). Higher frequencies of double
producers were found after vaccination in 2012 (p= 0.031) and
2013 (p= 0.173) (Fig. 4a). Detailed analysis of double producers
showed that the frequencies of IFN-γ+TNF-α+CD4+ T cells were
significantly boosted after each seasonal vaccination in 2012 (p=
0.021) and 2013 (p= 0.046) (Fig. 4b). The frequencies of
prevaccination IL-2+TNF-α+CD4+ cells were higher in 2013 than
2012, although not significant (p= 0.08).
We assessed the CD45RA−CCR7+central memory (CM) and
CD45RA−CCR7−effector memory (EM) CD4+ T-cell subsets secret-
ing IFN-γ or IL-2. We found that the long-lived CD4+ CM T cells
secreting IFN-γ (p= 0.042) or IL-2 (p= 0.038) were boosted after
vaccination in 2012, waned throughout the year although
persisting at comparatively higher levels than prevaccination
(Fig. 4c). Following 2013 vaccination, these responses were
boosted, but not significantly. The IFN-γ+ or IL-2+CD4+ EM
T cells remained stable throughout the two consecutive seasons
(Fig. 4e). Interestingly, higher frequencies of double producers IFN-
γ+TNF-α+CD4+ CM (p= 0.009) and EM (p= 0.030) T cells were
observed after vaccination in 2012, albeit not significant in 2013
(p= 0.223 and 0.079, respectively) (Fig. 4d, f).
Enhanced quantity and quality of T cells after repeated
vaccinations
We further investigated the long-term impact of repeated
vaccination on T cells during the 5 study-years by retrospectively
analyzing the H1N1pdm09-specific T-cell responses after pan-
demic vaccination in 200913 and comparing to the response after
seasonal vaccination in 2012 and 2013. Pre- and post-2009
pandemic vaccination data from nine HCWs who were subse-
quently annually vaccinated during 2010–2013 were included, of
which four HCWs had repeated paired pre- and postvaccination
data. The magnitude of prevaccination H1N1pdm09-specific IFN-γ-
secreting T cells was significantly higher in 2012 (p= 0.016) and
2013 (p= 0.025) compared to pre-pandemic vaccination in 2009,
although no significant boost was observed at 21 days post-
vaccination in these seasons (Fig. 5a, Supplementary-Fig. 2a).
By comparing cytokine profiles across these three seasons, we
found a significant increase in multifunctional CD4+ T cells
(secreting 2−3 cytokines) after repeated vaccinations (Fig. 5b,
Supplementary-Fig. 2b), indicating an enhanced T-cell quality over
the 5 years.14,15 The frequencies of triple producer (p= 0.008), and
double producers IFN-γ+TNF-α+ (p= 0.018) and IL-2+TNF-α+ (p=
0.034) CD4+ T cells prevaccination were significantly higher in
2013 than in 2009. Interestingly, the IFN-γ+TNF-α+ and IL-2+TNF-
α+CD4+ responses were boosted following 2009 vaccination (p=
0.031). In contrast, the frequencies of single IL-2-secreting T cells in
the last two seasons were significantly lower than in 2009 (p=
0.008). The prevaccination cytokine-profile radar chart (Fig. 5c)
shows that repeated vaccinations skewed the CD4+ T-cell
responses toward IFN-γ dominance and the IL-2 responses were
shifted from single to multifunctional IL-2 (double IL-2+TNF-α+ or
triple IFN-γ+IL-2+TNF-α+ co-producers).
Maintenance of high humoral responses after repeated
vaccinations
Throughout the 5 years of our study, the H1N1pdm09-specific HI
antibodies were significantly boosted after each vaccination (Fig.
6a). After the second vaccination, HI antibodies persisted above
the 50% protective threshold (HI titers ≥ 40) for 1-year postvacci-
nation in all HCWs, except one who had chronic respiratory and
neurological conditions. The prevaccination HI titers gradually
increased from 2009 to 2012, then were maintained between 2012
and 2013. The antibody fold-induction between pre- and
postvaccination titers was highest after the adjuvanted pandemic
vaccination in 2009 then declined after multiple vaccinations (Fig.
6b). The fold-induction after seasonal vaccination in 2012 and
2013 was significantly lower than in earlier seasons.
Fig. 3 The magnitude of cross-reactive CD4+ T-cell responses during seasons 2012 and 2013. The single IFN-γ- or IL-2-, or double-cytokine
IFN-γIL-2-secreting T cells against the CD4-specific conserved epitopes from viral external/internal proteins were measured in the T-cell
FluoroSpot assay a and e prevaccination (D0) (light) and at 21 days postvaccination (D21) (dark) in HCWs with annual repeated vaccination
(round) or c and g prior to the influenza season in 2012 (light) and 2013 (dark) in a control group of HCWs who were only vaccinated with the
AS03-adjuvanted pandemic H1N1pdm09 vaccine in 2009 (square).12 Each symbol represents one individual’s response with the horizontal
lines representing the mean magnitudes of cytokine-secreting cells per 106 PBMC with standard error of the mean (s.e.m.). The IFN-γ to IL-2
ratio was calculated for each participant at each time point and the mean ratios with s.e.m. are shown against the CD4-specific external/
internal epitopes b and f in HCWs with repeated vaccination or d and h a control group. The dotted line indicates the IFN-γ to IL-2 ratio of
1 showing a balanced IFN-γ and IL-2 response. An IFN-γ to IL-2 ratio above or below 1 shows a predominant IFN-γ or IL-2 response,
respectively. nsp > 0.05, *p < 0.05, **p < 0.01
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We further assessed the H1N1pdm09-specific MBC responses in
HCWs pre- and postvaccination in 2012 and 2013 (n= 5 due to
limited PBMC availability), while the 2009 data were retro-
spectively analyzed from nine HCWs.13 The prevaccination
H1N1pdm09-specific MBCs was significantly higher in 2012 and
2013 than in 2009 (Fig. 6c). Notably, MBCs were significantly
boosted following pandemic vaccination in 2009 (p= 0.031), but
not after seasonal vaccination in 2012 and 2013. The fold-
induction after vaccination was higher in 2009 than in 2013 (p=
0.061) (Fig. 6d).
We investigated the overall impact of repeated vaccination
against H1N1pdm09 on immune responses using radar charts. An
increase in both humoral and T-cell immunity specific for
H1N1pdm09 prevaccination were observed after 3−4 vaccinations
(Fig. 6e). Interestingly, MBCs and double producers CD4+ T cells
continue to increase from 2012 to 2013. The fold-induction of the
vaccine-induced responses postvaccination was highest after
adjuvanted pandemic vaccination in 2009 (Fig. 6f).
DISCUSSION
There is limited knowledge about the long-term impact of
repeated annual influenza vaccination on the influenza-specific
T-cell immunity despite decades of use of influenza vaccine. Here,
we provide unique data on humoral and T-cell responses after
repeated annual vaccination with the same H1N1pdm09 strain
from its introduction in 2009 and over four subsequent seasons.
Repeated vaccinations resulted in an increase in both the
quantity and the quality of H1N1pdm09-specific T-cell responses.
One study suggested that >20 IFN-γ-secreting T cells/106 PBMC as
detectable protective influenza-specific T cells at a population
level.8 In our repeatedly vaccinated HCW cohort, the
Fig. 4 The quality of CD4+ T-cell responses during seasons 2012 and 2013. The cytokine profile of H1N1pdm09-specific CD4+ T cells was
assessed by IFN-γ/IL-2/TNF-α intracellular cytokine-staining (ICS) assay prevaccination (D0) (light) and at 21 days postvaccination (D21) (dark)
in the 2012 and 2013 seasons. a The mean frequencies (%) of the triple producer (IFN-γ+IL-2+TNF-α+), double producers (IFN-γ+IL-2+, IFN-
γ+TNF-α+, IL-2+TNF-α+), and single producers (IFN-γ+, IL-2+, TNF-α+) with standard error of the mean (s.e.m.) are shown as bars. b The mean
frequencies with s.e.m. are presented for each of the three double-producer subsets. The memory CD4+ T-cell responses were assessed by
differentiating the three memory subsets CD45RA−CCR7+ central memory (CM), CD45RA−CCR7−effector memory (EM), and CD45RA+CCR7−
late effector memory (EMRA), from CD45RA+CCR7+ naïve T cells within the CD4+ population, then IFN-γ+ or IL-2+ cells were gated within
CD4+ CM or EM population (see gating strategy in Supplementary-Fig. 4). The mean frequencies with s.e.m. of the total IFN-γ- or IL-2-secreting
CD4+ c CM or e EM T cells pre- and postvaccination in seasons 2012 and 2013 are shown. The mean frequencies with s.e.m. are presented for
the IFN-γ+IL-2−TNF-α+ subset of the CD4+ d CM or f EM T cells. *p < 0.05, **p < 0.01
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prevaccination IFN-γ-secreting T cells increased significantly from
non-detectable (5 cells/106 PBMC) to persistently high numbers
(95 cells/106 PBMC) after 3−4 vaccinations, although we do not
have T-cell data from 2010 and 2011 to confirm whether these
cells increased continuously after each year of repeated vaccina-
tion until 2012 and 2013, similarly to the antibody responses.
Whereas in the absence of repeated vaccination, a decline in
H1N1pdm09-specific cytokine-secreting T cells from 2012 to 2013
was observed in single vaccinated individuals (Supplementary-Fig.
1a).12 Moreover, the quality of CD4+ T cells was improved with
higher multi-cytokine-secreting responses, associated with super-
ior function compared to single-cytokine producers.14,15 The boost
of IFN-γ+TNF-α+CD4+ responses after each vaccination in 2009,
2012, and 2013 suggests a continuous increase of these
responses. We hypothesize that the magnitude of T cells may
reach a plateau after 3−4 repeated vaccinations, like the
antibodies, while the quality of T cells continues to improve.
Although this study did not assess the quality of antibodies, our
earlier report showed that repeated vaccination maintained the
antibody avidity.16 This implies that repeated vaccination may
have a broader impact on immune responses, which are not
usually assessed in conventional vaccine immunogenicity stu-
dies.17 Future studies should therefore include diverse immuno-
logical assessments to better understand vaccine immunogenicity
in populations with different influenza exposure backgrounds.
We demonstrated that the H1N1pdm09-specific HI antibodies
were boosted after each vaccination during the 5 study-years. The
prevaccination antibodies increased each year until 2012 and
Fig. 5 The impact of repeated annual vaccinations on the magnitude and the quality of H1N1pdm09-specific T cells over 5 years. a The
magnitude of H1N1pdm09-specific IFN-γ-secreting T cells prevaccination (D0) (light) and at 21 days postvaccination (D21) (dark) were
enumerated in the IFN-γ T-cell ELISpot assay in 2009 (n= 9), and the IFN-γ/IL-2 FluoroSpot assay in 2012 and 2013. Each symbol represents
one individual’s response with the horizontal lines representing the mean magnitudes of IFN-γ-secreting cells per 106 PBMC with standard
error (s.e.m.). b The cytokine profile of H1N1pdm09-specific CD4+ T cells was assessed by the IFN-γ/IL-2/TNF-α intracellular cytokine-staining
(ICS) assay pre- and postvaccination in 2009, 2012, and 2013. The mean frequencies (%) with s.e.m. of each of the seven cytokine-combination
subsets are shown as bars. c Changes in the prevaccination cytokine profile of CD4+ T cells after 3–4 years of repeated vaccination. The fold-
changes of responses between 2009 (reference) and 2012 or 2013 were calculated for each participant and the log-transformed means of fold-
changes are presented in a radar chart. Value above or below 0 represents an increase or decline of response, respectively. *p < 0.05, **p < 0.01
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2013 persisting above the 50% protective threshold, whereas the
antibody fold-induction postvaccination declined and was lowest
in the last two seasons compared to previous seasons. This
suggests that repeated vaccinations sustain high protective
antibody levels rather than boosting them. The long-term
antibody persistence is probably due to activation of MBCs that
can undergo continuous proliferation and differentiation to
maintain constant levels of plasma cells and antibodies.18 T cells
Fig. 6 The overall impact of repeated annual vaccinations on T-cell and humoral responses. a The 5-year H1N1pdm09-specific antibody
responses following pandemic and repeated seasonal vaccinations were measured in the hemagglutination inhibition (HI) assay. Each symbol
represents one individual’s response with the horizontal lines representing the geometric mean HI titer with 95% confidence interval (CI)
prevaccination (D0) (light) and at 21 days postvaccination (D21) (dark) each year. The dotted line indicates the 50% protective threshold
defined as HI titer ≥ 40. b The HI antibody fold-induction between pre- and postvaccination (D21/D0) titers was calculated for each participant
at each time point. The horizontal lines represent the geometric mean HI antibody fold-induction with 95% CI. c The H1N1pdm09-specific
memory B-cell (MBC) responses pre- and postvaccination in seasons 2009, 2012, and 2013 were measured in the MBC ELISpot assay. The
horizontal lines represent the mean magnitudes of the H1N1pdm09-specific MBCs per 106 PBMC with standard error of the mean (s.e.m.). d
The MBC fold-induction between pre- and postvaccination (D21/D0) was calculated for each participant at each time point. The horizontal
lines represent the mean MBC fold-induction with s.e.m. e The fold-changes of prevaccination antibodies, MBCs, and T cells between 200913
and 2012 or 2013 were calculated for each participant and the log-transformed means of fold-changes are presented in a radar chart. Value
above or below 0 represents an increase or decline of response, respectively. f The log-transformed mean fold-induction of T-cell and humoral
responses between pre- and postvaccination (D21/D0) each year (2009, 2012, and 2013) is presented in a radar chart. The higher the value is
above 0, the higher the vaccine-induced response is after vaccination. *p < 0.05, **p < 0.01, ***p < 0.001
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also contribute to induction and maintenance of antibodies by
providing help to activate naïve and MBCs.19 This hypothesis was
supported by the significantly higher H1N1pdm09-specific MBCs
and T cells observed after 3−4 repeated vaccinations. Moreover,
the decline in antibody fold-induction observed in later seasons
may be due to the presence of high prevaccination HI antibodies,
which may block the vaccine epitopes, resulting in a reduction of
B- and T-cell activation,20–22 and therefore limit the boosting
ability of subsequent vaccinations.
The controversy of annual influenza vaccination policy involves
conflicting reports on the impact of repeated vaccination, which
reported either no significant interference or a reduction in
antibody responses and vaccine effectiveness (VE).9–11,23,24 In
studies that found that repeated vaccination led to decreased
protection, this was mainly related to the H3N2 viruses. The
H3N2 subtype has been associated with lower VE and undergoes
more frequent antigenic changes compared to the H1N1 and B
viruses included in the seasonal vaccines.25 A recent study
investigating the impact of repeated vaccination against
H1N1pdm09 on VE suggests that VE was highest after 2−3
vaccinations and reduced in vaccinees immunized with >3
vaccinations.11 Our study did not find a reduction in H1N1-
specific immune responses after 3−4 vaccinations, although
protection was not assessed. Our findings show the maintenance
of H1N1pdm09-specific antibodies, MBCs and T cells at high levels
with improved quality of CD4+ T cells after 3−4 repeated
vaccinations. However, enhanced T-cell responses do not prevent
infection, the outcome in most studies investigating protection
use, but reduce the severity of illness.5–8 We suggest that broader
outcome measures of protection, such as severity scores or time to
recover, should be incorporated into future studies together with
various immunological assessments to better evaluate the impact
of repeated vaccination. Taken together, we support the
continuation of the current recommendation of annual influenza
vaccination, even with the same vaccine component, to provide
protection against all circulating seasonal strains. Our findings
point to the importance of inclusion of influenza vaccination
history, when evaluating vaccine immunogenicity and
effectiveness.
Remarkably, the long-lived H1N1pdm09-specific CD4+ CM
T cells were boosted after vaccination. Since CM cells can rapidly
proliferate and differentiate into effector cells upon antigen
encounter,26 the persistent CD4+ CM and EM responses following
repeated vaccination may provide long-lasting protection. These
findings agree with our previous report12 and provide an
explanation for the long-term maintenance of IFN-γ+ and multi-
functional CD4+ T cells in repeatedly vaccinated HCWs, which was
not observed in HCWs immunized with only pandemic vaccina-
tion. Our findings suggest that repeated vaccination optimizes the
quantitative responses while shifting the influenza-specific immu-
nity towards long-term memory and multifunctional responses.
However, this hypothesis needs to be verified with the other
influenza vaccine strains, H3N2 and B viruses, which change more
frequently than H1N1 viruses.
Influenza-specific CD4+ T cells can recognize conserved
epitopes from heterosubtypic influenza A viruses and provide
cross-protection5 and are boosted after a single vaccination.13,27,28
We extended these findings by separately investigating the cross-
reactive CD4+ responses to conserved viral external or internal
epitopes following repeated vaccination, as these cells may be
phenotypically different with distinct potential functions.29–32
After 3−4 repeated vaccinations, a decline in IL-2 responses
resulting in a trend of increased IFN-γ dominance against viral
internal epitopes was observed, which agrees with previous
reports.33,34 Long-term exposure to influenza through vaccination
or infection may shape the T-cell responses towards conserved
epitopes that are repeatedly recognized by influenza-specific
memory T cells. We hypothesize that these responses are
multifunctional with predominantly IFN-γ and a low level of IL-2.
Interestingly, analyses of the quality of H1N1pdm09-specific CD4+
T cells after repeated vaccinations provided a potential explana-
tion supporting this hypothesis. We found the boosting of IFN-
γ+TNF-α+CD4+ T-cell responses following each vaccination, the
increased multi-cytokine-secreting and decreased single IL-2-
secreting cells after 3−4 repeated vaccinations. The ratio of IFN-
γ to IL-2-secreting cells, calculated using the cytokine profile data
showed that the H1N1pdm09-specific CD4+ T cells remained IL-2
enriched in 2009 but changed toward predominantly IFN-γ
secretion in 2012 and 2013 (Supplementary-Fig. 3). However,
whether this IFN-γ dominance in cross-reactive CD4+ T cells
indicates a greater potential for help and/or other functions will
need to elucidate in further studies.
We faced difficulties due to the long follow-up period, such as
losing participants and missing samples. The strict inclusion
criteria that only HCWs repeatedly vaccinated for 5 years greatly
limited the sample size of our study. However, this design allows
us to study the long-term impact of repeated vaccinations on
immune responses while clarifying the effect of vaccination
sequence without the bias of missing vaccination history. As HCWs
who were repeatedly vaccinated for 5 years were identified in the
last two seasons, the T-cell responses in 2009 were retrospectively
evaluated. Although the low number of participants with
accessible data and the lack of 2010 and 2011 information on
T cells limited our observation, the immune responses after
repeated vaccinations were undoubtedly enhanced. As memory T-
cell responses are rapidly generated, we cannot dismiss the
possibility of T-cell expansion at 7–14 days,13 time points that
were not investigated in this study. Further studies are required to
confirm our findings in larger populations with documented
vaccination history, and to evaluate both antibody and T-cell
responses against other vaccine strains after repeated annual
vaccination.
In conclusion, we provide a unique overview of the long-term
impact of repeated annual influenza vaccination against the same
vaccine strain on humoral and T-cell immunity. Repeated
vaccinations with H1N1pdm09 not only maintained the high
magnitude of strain-specific HI antibodies and T cells, and cross-
reactive IFN-γ+CD4+ T cells, but also increased MBC and multi-
functional CD4+ T-cell responses. This study highlights a broad
immunological impact of repeated vaccination and supports the
current recommendation of annual seasonal influenza vaccination.
Our findings suggest that routine collection of influenza vaccina-
tion history and diverse immunological approaches should be
included when evaluating vaccine immunogenicity and
effectiveness.
METHODS
Study population and sampling
An open-label 5-year extension of a single-arm clinical trial was conducted
in HCWs (Haukeland University Hospital, Norway) vaccinated with the 2009
AS03-adjuvanted pandemic H1N1pdm09 vaccine (www.Clinicaltrials.gov,
NCT01003288). The study was approved by the regional ethics committee
(REKVest-2012/1772) and the Norwegian Medicines Agency.35 All partici-
pants provided written informed consent before inclusion and new
consent for the follow-up blood samples. During 2010–2013, HCWs were
annually vaccinated with the non-adjuvanted seasonal trivalent inactivated
vaccine (Vaxigrip, Sanofi Pasteur or Influvac, Abbott Laboratories) contain-
ing the H1N1pdm09 as the A/H1N1 component and different A/H3N2 and
B viruses (Fig. 1). Serum samples were collected pre- and 21 days
postvaccination for each season from 2009 to 2013. HCWs who provided
additional PBMC samples pre- and 21-day postvaccination in 2012 and
2013 were included in this study.
Sera were separated from clotted blood and stored at −80 °C until
analyzed. PBMC were isolated and cryopreserved at −150 °C in 90% fetal
bovine serum/10% dimethyl sulfoxide until analyzed.12
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Hemagglutination inhibition (HI) assay
Receptor destroying enzyme-treated sera were tested in duplicate with
0.7% turkey red blood cells (TRBC) and eight HA units of inactivated A/
California/07/2009 (H1N1) antigen, as described previously.35 The HI titer
was the reciprocal of the highest serum dilution causing 50% inhibition of
hemagglutination. Titers <10 were assigned a value of 5 for calculation
purposes. Sera <40 were screened for nonspecific binding and pre-
adsorbed with TRBC before re-analyzing.
T-cell FluoroSpot assay
PBMC were stimulated with the split H1N1pdm09 antigen, the H1N1-
specific M1, NP, or PB1 peptide pools (BEI Resources), or the conserved
CD4 internal or external peptide pools to measure the IFN-γ- and/or IL-2-
secreting T-cell responses, as described earlier.12,36 The M1, NP, or PB1
peptide pools included overlapping epitopes that covered the complete
sequence of the three proteins. The CD4 peptide pools were chemically
synthesized and consisted of HLA−class-II-restricted T-cell epitopes from
internal or external viral proteins that are conserved among influenza A
subtypes with high prevalence and HLA−supertype coverage (Supple-
mentary-Tables 2, 3).36 Cytokine-secreting cells were counted and the
background from non-stimulated cells was subtracted from stimulation
responses.
Intracellular cytokine-staining (ICS) assay
PBMC were stimulated with the split H1N1pdm09 antigen to measure the
IFN-γ-, IL-2- and/or TNF-α-secreting CD4+ T-cell responses, as described
previously.12 Data were acquired on an LSRFortessa flow cytometer and
analyzed in FlowJo version-10 (see Supplementary-Fig. 4 for the gating
strategy).
Memory B-cell (MBC) ELISpot assay
The H1N1pdm09-specific IgG+MBC responses were measured by the
ELISpot assay, as described elsewhere.37
Statistical analyses
Comparisons of the T-cell responses assessed in the FluoroSpot or ICS
assays in 2012 and 2013 and the 5-year log-transformed HI antibody titers
were performed using the nonparametric repeated-measure Friedman
test, followed by the Dunn−Bonferroni post-hoc test. The retrospective
data for IFN-γ-secreting T cells, cytokine profile and MBCs in 2009 were
compared to the prospective data in 2012 or 2013 using the nonpara-
metric Kruskal−Wallis or Mann−Whitney test, as appropriate, with
Bonferroni correction. Adjusted p values < 0.05 were considered statisti-
cally significant. Analyses were performed in SPSS-Statistics version-24 and
visualized in Prism version-7.
Data availability
The data that support the findings of this study are available from the
corresponding author upon reasonable request.
ACKNOWLEDGEMENTS
We especially thank all the HCWs who participated in this study, Marianne Sævik and
Jane Kristin Nøstbakken for invaluable technical and logistical assistance, and the
GlaxoSmithKline (Belgium) for kindly providing the split virus vaccine antigen. The
study was funded intramurally by the Influenza Centre at the University of Bergen
and the Bergen Clinical Vaccine Consortium. The Influenza Centre is funded by the
Ministry of Health and Care Services, Norway, the Norwegian Research Council
Globvac program (220670/H10), the European Union (Univax 601738 and EU
IMI115672, FLUCOP), EuroNanoMed2 (271160), Helse Vest and the K.G. Jebsen Centre
for Influenza Vaccine Research.
AUTHOR CONTRIBUTIONS
R.J.C. and S.M. conceived and designed the study. M.-C.T. and S.L.L. developed the
assays and performed the experiments. M.-C.T. analyzed the data. M.-C.T., R.J.C., F.Z.,
and S.S. interpreted the data. M.-C.T., R.J.C., F.Z., S.S., and S.M. contributed to writing
of the manuscript. All authors read and approved the final version of the paper.
ADDITIONAL INFORMATION
Supplementary information accompanies the paper on the npj Vaccines website
(https://doi.org/10.1038/s41541-018-0069-1).
Competing interests: The authors declare no competing interest.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
REFERENCES
1. Costantino, C. & Vitale, F. Influenza vaccination in high-risk groups: a revision of
existing guidelines and rationale for an evidence-based preventive strategy. J.
Prev. Med. Hyg. 57, E13–E18 (2016).
2. Maltezou, H. C. & Poland, G. A. Immunization of health-care providers: necessity
and public health policies. Healthcare (Basel, Switzerland) 4, https://doi.org/
10.3390/healthcare4030047 (2016).
3. Lansbury, L. E. et al. Effectiveness of 2009 pandemic influenza A(H1N1) vaccines: a
systematic review and meta-analysis. Vaccine 35, 1996–2006 (2017).
4. Cox, R. J. Correlates of protection to influenza virus, where do we go from here?
Human Vaccin. Immunother. 9, 405–408 (2013).
5. Wilkinson, T. M. et al. Preexisting influenza-specific CD4+ T cells correlate with
disease protection against influenza challenge in humans. Nat. Med. 18, 274–280
(2012).
6. Sridhar, S. et al. Cellular immune correlates of protection against symptomatic
pandemic influenza. Nat. Med. 19, 1305–1312 (2013).
7. Wang, Z. et al. Recovery from severe H7N9 disease is associated with diverse
response mechanisms dominated by CD8(+) T cells. Nat. Commun. 6, 6833
(2015).
8. Hayward, A. C. et al. Natural T cell-mediated protection against seasonal and
pandemic influenza. Results of the Flu Watch Cohort Study. Am. J. Respir. Crit.
Care Med. 191, 1422–1431 (2015).
9. Beyer, W. E., de Bruijn, I. A., Palache, A. M., Westendorp, R. G. & Osterhaus, A. D.
Protection against influenza after annually repeated vaccination: a meta-analysis
of serologic and field studies. Arch. Intern. Med. 159, 182–188 (1999).
10. Belongia, E. A. et al. Repeated annual influenza vaccination and vaccine effec-
tiveness: review of evidence. Expert Rev. Vaccin. 16, 1–14 (2017).
11. Martinez-Baz, I. et al. Effect of repeated vaccination with the same vaccine
component against 2009 pandemic influenza A(H1N1) virus. J. Infect. Dis. 215,
847–855 (2017).
12. Trieu, M. C. et al. Long-term maintenance of the influenza-specific cross-reactive
memory CD4+ T-cell responses following repeated annual influenza vaccination.
J. Infect. Dis. 215, 740–749 (2017).
13. Lartey, S. et al. Single dose vaccination of the ASO3-adjuvanted A(H1N1)pdm09
monovalent vaccine in health care workers elicits homologous and cross-reactive
cellular and humoral responses to H1N1 strains. Human Vaccin. Immunother. 11,
1654–1662 (2015).
14. Kannanganat, S., Ibegbu, C., Chennareddi, L., Robinson, H. L. & Amara, R. R.
Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to
single-cytokine-producing cells. J. Virol. 81, 8468–8476 (2007).
15. Seder, R. A., Darrah, P. A. & Roederer, M. T-cell quality in memory and protection:
implications for vaccine design. Nat. Rev. Immunol. 8, 247–258 (2008).
16. Eidem, S. et al. Persistence and avidity maturation of antibodies to A(H1N1)
pdm09 in healthcare workers following repeated annual vaccinations. Vaccine 33,
4146–4154 (2015).
17. Wijnans, L. & Voordouw, B. A review of the changes to the licensing of influenza
vaccines inEurope. Influenza Other Respir. Virus. 10, 2–8 (2016).
18. Bernasconi, N. L., Traggiai, E. & Lanzavecchia, A. Maintenance of serological
memory by polyclonal activation of human memory B cells. Sci. (New York, NY)
298, 2199–2202 (2002).
19. Lanzavecchia, A. et al. Understanding and making use of human memory B cells.
Immunol. Rev. 211, 303–309 (2006).
20. Andrews, S. F. et al. High preexisting serological antibody levels correlate with
diversification of the influenza vaccine response. J. Virol. 89, 3308–3317 (2015).
21. Sasaki, S. et al. Influence of prior influenza vaccination on antibody and B-cell
responses. PLoS ONE 3, e2975 (2008).
22. Dolfi, D. V. et al. Vaccine-induced boosting of influenza virus-specific CD4 T cells
in younger and aged humans. PLoS ONE 8, e77164 (2013).
23. Ramsay, L. C. et al. The impact of repeated vaccination on influenza
vaccine effectiveness: a systematic review and meta-analysis. Bmc Med. 15,
159 (2017).
24. McLean, H. Q. et al. Impact of repeated vaccination on vaccine effectiveness
against influenza A(H3N2) and B during 8 seasons. Clin. Infect. Dis. 59, 1375–1385
(2014).
Repeated vaccination boosts antibodies and T-cellsy
M-C Trieu et al.
9
Published in partnership with the Sealy Center for Vaccine Development npj Vaccines (2018)  37 
25. Belongia, E. A. et al. Variable influenza vaccine effectiveness by subtype: a sys-
tematic review and meta-analysis of test-negative design studies. Lancet Infect.
Dis. 16, 942–951 (2016).
26. Sallusto, F., Geginat, J. & Lanzavecchia, A. Central memory and effector memory T
cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22,
745–763 (2004).
27. Bonduelle, O. et al. Longitudinal and integrative biomodeling of effector and
memory immune compartments after inactivated influenza vaccination. J.
Immunol. (Baltimore, Md.: 1950) 191, 623–631 (2013).
28. Schmidt, T. et al. CD4+ T-cell immunity after pandemic influenza vaccination
cross-reacts with seasonal antigens and functionally differs from active influenza
infection. Eur. J. Immunol. 42, 1755–1766 (2012).
29. Leddon, S. A., Richards, K. A., Treanor, J. J. & Sant, A. J. Abundance and specificity
of influenza reactive circulating memory follicular helper and non-follicular
helper CD4 T cells in healthy adults. Immunology 146, 157–162 (2015).
30. DiPiazza, A., Richards, K. A., Knowlden, Z. A., Nayak, J. L. & Sant, A. J. The Role of
CD4 T cell memory in generating protective immunity to novel and potentially
pandemic strains of influenza. Front. Immunol. 7, 10 (2016).
31. Scherle, P. A. & Gerhard, W. Differential ability of B cells specific for external vs.
internal influenza virus proteins to respond to help from influenza virus-specific
T-cell clones in vivo. Proc. Natl. Acad. Sci. USA 85, 4446–4450 (1988).
32. Alam, S., Knowlden, Z. A., Sangster, M. Y. & Sant, A. J. CD4 T cell help is limiting
and selective during the primary B cell response to influenza virus infection. J.
Virol. 88, 314–324 (2014).
33. Sridhar, S. et al. Predominance of heterosubtypic IFN-gamma-only-secreting
effector memory T cells in pandemic H1N1 naive adults. Eur. J. Immunol. 42,
2913–2924 (2012).
34. Weaver, J. M. et al. Increase in IFNgamma(-)IL-2(+) cells in recent human CD4 T
cell responses to 2009 pandemic H1N1 influenza. PLoS ONE 8, e57275 (2013).
35. Madhun, A. S. et al. An adjuvanted pandemic influenza H1N1 vaccine provides
early and long term protection in health care workers. Vaccine 29, 266–273
(2010).
36. Savic, M. et al. Epitope specific T-cell responses against influenza A in a healthy
population. Immunology 147, 165–177 (2016).
37. Crotty, S., Aubert, R. D., Glidewell, J. & Ahmed, R. Tracking human antigen-specific
memory B cells: a sensitive and generalized ELISPOT system. J. Immunol. Methods
286, 111–122 (2004).
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2018
Repeated vaccination boosts antibodies and T-cellsy
M-C Trieu et al.
10
npj Vaccines (2018)  37 Published in partnership with the Sealy Center for Vaccine Development
